AlphaQuest LLC Has $333,000 Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

AlphaQuest LLC raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 49,687.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,983 shares of the biopharmaceutical company’s stock after buying an additional 3,975 shares during the period. AlphaQuest LLC’s holdings in Intra-Cellular Therapies were worth $333,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Lisanti Capital Growth LLC raised its position in shares of Intra-Cellular Therapies by 24.9% in the 4th quarter. Lisanti Capital Growth LLC now owns 72,600 shares of the biopharmaceutical company’s stock valued at $6,064,000 after acquiring an additional 14,485 shares during the period. Candriam S.C.A. raised its holdings in Intra-Cellular Therapies by 30.6% in the fourth quarter. Candriam S.C.A. now owns 214,320 shares of the biopharmaceutical company’s stock worth $17,900,000 after purchasing an additional 50,188 shares during the period. Inceptionr LLC acquired a new stake in Intra-Cellular Therapies in the fourth quarter worth $1,034,000. Raymond James Financial Inc. acquired a new position in shares of Intra-Cellular Therapies in the 4th quarter valued at $76,451,000. Finally, Arizona State Retirement System grew its holdings in shares of Intra-Cellular Therapies by 0.8% in the 4th quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock valued at $2,302,000 after buying an additional 206 shares during the period. Institutional investors own 92.33% of the company’s stock.

Analyst Upgrades and Downgrades

ITCI has been the topic of several research analyst reports. Canaccord Genuity Group lowered Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their target price for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Royal Bank of Canada restated a “sector perform” rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $140.00 to $132.00 in a report on Monday, February 24th. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $131.26 on Friday. The stock’s 50-day simple moving average is $123.95 and its 200 day simple moving average is $95.39. Intra-Cellular Therapies, Inc. has a 52-week low of $63.87 and a 52-week high of $131.40. The company has a market cap of $13.96 billion, a P/E ratio of -150.87 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.